Nkarta, Inc. (NASDAQ:NKTX) Insider David Shook Sells 8,638 Shares

Nkarta, Inc. (NASDAQ:NKTX) insider David Shook sold 8,638 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $19,003.60. Following the sale, the insider now directly owns 190,955 shares of the company’s stock, valued at approximately $420,101. This represents a 4.33 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Nkarta Stock Down 0.8 %

Shares of Nkarta stock opened at $2.47 on Friday. Nkarta, Inc. has a 52 week low of $2.08 and a 52 week high of $16.24. The business’s fifty day simple moving average is $2.52 and its 200-day simple moving average is $4.18.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Erste Asset Management GmbH acquired a new stake in shares of Nkarta during the third quarter valued at about $33,000. GAMMA Investing LLC increased its holdings in Nkarta by 110.9% in the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock valued at $45,000 after purchasing an additional 5,243 shares during the last quarter. Forefront Analytics LLC acquired a new stake in Nkarta in the 2nd quarter valued at approximately $70,000. Intech Investment Management LLC purchased a new stake in Nkarta in the third quarter valued at approximately $74,000. Finally, SG Americas Securities LLC acquired a new position in Nkarta during the third quarter worth $93,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on NKTX shares. Rodman & Renshaw initiated coverage on Nkarta in a report on Wednesday, October 9th. They set a “buy” rating and a $14.00 target price on the stock. HC Wainwright lowered their price objective on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Mizuho cut their target price on Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. Needham & Company LLC lowered their price target on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Finally, RODMAN&RENSHAW raised shares of Nkarta to a “strong-buy” rating in a report on Wednesday, October 9th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $15.00.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.